Editorial
Weight gain on dolutegravir: Association is not the same as causation
Submitted: 31 March 2023 | Published: 15 May 2023
About the author(s)
Gary Maartens, Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South AfricaPhumla Sinxadi, Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
W.D. Francois Venter, Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Abstract
Keywords
Metrics
Total abstract views: 1678Total article views: 2074
Crossref Citations
1. Assessment of weight gain in adult patients living with HIV receiving first‐line dolutegravir‐based or efavirenz‐based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study
Shobna Sawry, Kassahun Ayalew, Gloria Maimela, Melissa Briggs‐Hagen, Marelize van Wyk‐Heath, Simangele Mthethwa, Sannie Shai, Nkululeko N. Mngomezulu, Lawrence Tlhowe, Josephine Achere‐Darko, Jason Bedford, Catherine E. Martin, Lee Fairlie, John Imrie
HIV Medicine year: 2024
doi: 10.1111/hiv.13638